(A) Effect of mTOR inhibitors on PCSK9 mRNA expression. Five selected resistant and sensitive Lymphoblastoid Cell Lines (LCLs) for mTOR inhibitors were treated with sirolimus (0.2 μM), everolimus (0.33 μM) or DMSO for 3 d. QRT-PCR was performed to measure the expression of PCSK9 pre and post drug treatment. (B) Representative Western blot for protein expression. Western blot analysis with antibodies against mTOR, phosphorylated Ser2448mTOR, PCSK9 was performed using protein lysate from cells treated under the same conditions as those in (A). Actin was used as a loading control. (C) Quantification of relative protein levels for all 5 LCLs. Results were calculated with Grey-scan value. * p